Ameriprise
ESPR

Ameriprise’s Esperion Therapeutics ESPR Stock Holding History

Ameriprise’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-42,951
Closed -$267K – 3969
2022
Q4 		$267K Buy
42,951
+12
+0% +$86 ﹤0.01% 3624
2022
Q3 		$287K Sell
42,939
-1,970
-4% -$13.5K ﹤0.01% 3596
2022
Q2 		$286K Buy
44,909
+26,510
+144% +$150K ﹤0.01% 3574
2022
Q1 		$86K Sell
18,399
-94,245
-84% -$404K ﹤0.01% 3854
2021
Q4 		$564K Buy
+112,644
New +$902K ﹤0.01% 3477
2020
Q2 		– Sell
-5,983
Closed -$327K – 3694
2020
Q1 		$327K Buy
+5,983
New +$316K ﹤0.01% 3279
2019
Q3 		– Sell
-25,640
Closed -$1.19M – 3719
2019
Q2 		$1.19M Buy
25,640
+145
+0.6% +$6.81K ﹤0.01% 2990
2019
Q1 		$1.02M Sell
25,495
-70
-0.3% -$3.14K ﹤0.01% 3033
2018
Q4 		$1.18M Buy
25,565
+16,400
+179% +$790K ﹤0.01% 2882
2018
Q3 		$406K Buy
+9,165
New +$421K ﹤0.01% 3356
2018
Q2 		– Sell
-21,472
Closed -$1.55M – 3655
2018
Q1 		$1.55M Sell
21,472
-3,762
-15% -$276K ﹤0.01% 2787
2017
Q4 		$1.66M Buy
25,234
+321
+1% +$17.3K ﹤0.01% 2750
2017
Q3 		$1.25M Sell
24,913
-9,368
-27% -$452K ﹤0.01% 2866
2017
Q2 		$1.59M Sell
34,281
-8,110
-19% -$298K ﹤0.01% 2722
2017
Q1 		$1.5M Buy
+42,391
New +$971K ﹤0.01% 2709
2015
Q2 		– Sell
-17,587
Closed -$1.63M – 4036
2015
Q1 		$1.63M Sell
17,587
-22,061
-56% -$1.42M ﹤0.01% 2683
2014
Q4 		$1.6M Buy
+39,648
New +$1.21M ﹤0.01% 2650

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Ameriprise's ESPR Position: Q1 2023 in Review

Ameriprise sold out of Esperion Therapeutics (ESPR) in Q1 2023, closing a stake of 42,951 shares — an estimated $267K sold.

Ameriprise first reported a position in ESPR in Q4 2014 and held it in 17 quarters. The position peaked at $1.66M in Q4 2017. 164 funds tracked by Wall St. Rank hold ESPR as of Q1 2023.

  • Ameriprise reported no remaining Esperion Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ameriprise sold 42,951 Esperion Therapeutics shares in Q1 2023, an estimated $267K.
  • Ameriprise first reported a position in Esperion Therapeutics in Q4 2014 and held it in 17 quarters.
  • Ameriprise's Esperion Therapeutics position peaked at $1.66M in Q4 2017.
  • 164 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2023.

Based on Ameriprise's 13F filing for Q1 2023, filed 15 May 2023.